Use of topical corticosteroids in children with eczema does not have negative side effects

A new study published in the journal Pediatric Dermatology reveals that routine, long-term use of topical corticosteroids (TCS) for treating children with eczema does not cause any significant, negative side effects.

Parental phobia of TCS is widespread and leads to poorly managed in . The commonest fear is that TCS use will "thin the skin." Parents fears are also shared by many , including pharmacists.

Led by Gayle Fischer, MBBS, FACD, of The University of Sydney, researchers studied 92 children, 70 of which were part of the study/dermatitis group while the other 22 were categorized in a control group. Researchers convinced the parents of these 70 children to use enough TCS to control their children's eczema very well so that they were virtually free of eczema consistently. The 22 children in the control group were not using TCS.

Researchers then evaluated the children by examining them for any signs of skin thinning and by also examining their treated and untreated skin by dermoscopy, a technique which utilizes a mini-microscope to search for even the most subtle signs of TCS side effects.

They found that the children using TCS had no evidence of skin thinning even though they were using enough TCS to produce complete control of their eczema. These children were no different to the children who were not using TCS at all.

"Our results show that normal routine use of TCS does not cause skin thinning, and parents should be reassured. We hope that our work will give them the confidence to use TCS safely and effectively" Fischer notes.

add to favorites email to friend print save as pdf

Related Stories

India's TCS quarterly profit jumps 21 percent

Jul 15, 2010

India's largest software exporter Tata Consultancy Services (TCS) reported Thursday its quarterly net profit jumped 21 percent, beating forecasts, as demand for outsourcing improved.

India software giant TCS profits up 30%

Jan 17, 2011

India's largest software exporter Tata Consultancy Services on Monday said profits rose nearly 30 percent in the third quarter, beating forecasts, as outsourcing orders strengthened.

India's TCS announces 29 pct quarterly profit jump

Oct 16, 2009

India's biggest software services exporter, TCS, reported Friday that its quarterly net profit rose by 29 percent as the company sealed more deals in a better global business environment.

Recommended for you

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

Drug-coated balloon catheter approved

Oct 13, 2014

(HealthDay)—The first drug-coated balloon catheter designed to clear narrowed or blocked arteries in the thigh and knee has been approved by the U.S. Food and Drug Administration.

User comments